Last week it was announced that NaDeNo has reached an important milestone with CTA approval for the Phase I first-in-human clinical trial of its lead candidate, PACAB-002, in ovarian cancer.
LINK Medical have supported NaDeNo with protocol development, including PK, dose and trial-design discussions, CTA submission and site coordination.
Congratulations to the NaDeNo team on this important achievement. We are proud to be part of the journey, bringing the program into the clinic.